CA3192600A1 - Adeno-associated virus compositions having preferred expression levels - Google Patents
Adeno-associated virus compositions having preferred expression levelsInfo
- Publication number
- CA3192600A1 CA3192600A1 CA3192600A CA3192600A CA3192600A1 CA 3192600 A1 CA3192600 A1 CA 3192600A1 CA 3192600 A CA3192600 A CA 3192600A CA 3192600 A CA3192600 A CA 3192600A CA 3192600 A1 CA3192600 A1 CA 3192600A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- further provided
- amino acid
- acid selected
- aav capsid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068614P | 2020-08-21 | 2020-08-21 | |
| US63/068,614 | 2020-08-21 | ||
| PCT/US2021/046904 WO2022040527A2 (en) | 2020-08-21 | 2021-08-20 | Adeno-associated virus compositions having preferred expression levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3192600A1 true CA3192600A1 (en) | 2022-02-24 |
Family
ID=80323313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3192600A Pending CA3192600A1 (en) | 2020-08-21 | 2021-08-20 | Adeno-associated virus compositions having preferred expression levels |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230303630A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4199972A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023538129A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117321213A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021329527A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3192600A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022040527A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| US12630842B2 (en) | 2020-05-13 | 2026-05-19 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| EP4322976A4 (en) * | 2021-04-13 | 2025-06-25 | Capsida, Inc. | AAV COMPOSITIONS WITH HIGH EXPRESSION LEVELS IN THE BRAIN |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| EP4426716A1 (en) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CN119095867A (zh) * | 2022-03-24 | 2024-12-06 | 卡西达公司 | 具有优选的脑富集的所选aav组合物 |
| CN114774373B (zh) * | 2022-04-27 | 2024-07-05 | 北京市农林科学院 | 信鸽新城疫病毒基因工程改造弱毒株及其制备方法和应用 |
| EP4269426A1 (en) * | 2022-04-29 | 2023-11-01 | Ospedale San Raffaele S.r.l. | Gene therapy |
| WO2023215546A2 (en) * | 2022-05-06 | 2023-11-09 | Capsida, Inc. | Adeno-associated virus compositions having increased brain enrichment |
| EP4526325A4 (en) * | 2022-05-17 | 2026-08-05 | Capsida Inc | SELECTED ADENE-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED LEVELS OF CEREBRAL, SPINAL CORD AND/OR CARDIAC EXPRESSION |
| WO2023244919A1 (en) * | 2022-06-16 | 2023-12-21 | Capsida, Inc. | Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichment |
| AU2023363990A1 (en) * | 2022-10-19 | 2025-05-08 | Capsida Biotherapeutics, Inc. | Adeno-associated virus compositions having preferred brain enrichment and low liver enrichment |
| AU2023364350A1 (en) | 2022-10-19 | 2025-06-05 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
| JP2026509271A (ja) | 2023-03-10 | 2026-03-17 | ダイノ セラピューティクス,インコーポレーテッド | カプシドポリペプチドおよびその使用方法 |
| CN120660140A (zh) * | 2023-03-27 | 2025-09-16 | 浙江大学 | 氨基酸序列的生成与筛选方法及其系统 |
| KR20260045798A (ko) * | 2023-06-30 | 2026-04-03 | 캡시다 바이오테라퓨틱스, 인크. | 증가된 뇌 풍부화를 갖는 아데노-연관 바이러스 조성물 |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2025213066A1 (en) * | 2024-04-05 | 2025-10-09 | Capsida Biotherapeutics, Inc. | Adeno-associated virus compositions for treating parkinson's disease (pd) |
| WO2025231383A1 (en) * | 2024-05-03 | 2025-11-06 | Capsida Biotherapeutics, Inc. | Compositions and methods of delivering a therapeutic across the blood-brain barrier via the pl16 receptor |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710036B2 (en) * | 1997-07-25 | 2004-03-23 | Avigen, Inc. | Induction of immune response to antigens expressed by recombinant adeno-associated virus |
| DK3693025T3 (da) * | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| DE102014207498A1 (de) * | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark |
| AU2016366549B2 (en) * | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| CN109640949B (zh) * | 2016-07-29 | 2022-11-25 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体和其使用方法 |
| JP2021530218A (ja) * | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| EP3830107A2 (en) * | 2018-08-03 | 2021-06-09 | Voyager Therapeutics, Inc. | Aav variants with enhanced tropism |
| US11149256B2 (en) * | 2018-09-26 | 2021-10-19 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| US12281321B2 (en) * | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN113166208B (zh) * | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
-
2021
- 2021-08-20 EP EP21859200.4A patent/EP4199972A4/en active Pending
- 2021-08-20 CA CA3192600A patent/CA3192600A1/en active Pending
- 2021-08-20 CN CN202180071840.5A patent/CN117321213A/zh active Pending
- 2021-08-20 JP JP2023512697A patent/JP2023538129A/ja active Pending
- 2021-08-20 WO PCT/US2021/046904 patent/WO2022040527A2/en not_active Ceased
- 2021-08-20 US US18/022,056 patent/US20230303630A1/en active Pending
- 2021-08-20 AU AU2021329527A patent/AU2021329527A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117321213A (zh) | 2023-12-29 |
| JP2023538129A (ja) | 2023-09-06 |
| EP4199972A2 (en) | 2023-06-28 |
| US20230303630A1 (en) | 2023-09-28 |
| EP4199972A4 (en) | 2025-01-15 |
| WO2022040527A2 (en) | 2022-02-24 |
| WO2022040527A3 (en) | 2022-05-05 |
| AU2021329527A1 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230303630A1 (en) | Adeno-associated virus compositions having preferred expression levels | |
| US20250281643A1 (en) | Selected aav compositions having preferred brain enrichment | |
| US20250082779A1 (en) | Adeno-associated virus compositions having increased brain enrichment | |
| US20240150410A1 (en) | Aav compositions having high expression levels in brain | |
| US20250249124A1 (en) | Adeno-associated virus compositions having increased brain enrichment | |
| US20260028595A1 (en) | Selected adeno-associated virus compositions having preferred brain, spinal cord, and/or heart expression levels | |
| US20250188129A1 (en) | Selected aav compositions having preferred brain enrichment | |
| US20260139010A1 (en) | Adeno-associated virus compositions having preferred brain enrichment and low liver enrichment | |
| US20250346637A1 (en) | Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichment | |
| US20250255989A1 (en) | Adeno-associated virus compositions having increased brain enrichment and/or heart enrichment | |
| WO2025106565A1 (en) | Adeno-associated virus compositions having increased central nervous system, brain, and/or spinal cord enrichment | |
| EP4735614A1 (en) | Adeno-associated virus compositions having increased brain enrichment | |
| WO2026050233A1 (en) | Novel adeno-associated virus compositions having increased brain enrichment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240816 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240816 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250807 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250807 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250819 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251006 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251006 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251006 |